BMC Cancer, 2022 Background Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in North America. Previous studies have shown improved progression free survival (PFS) and response rates in unfit patients treated with obinutuzumab compared to other ...
Nicole Bourrier +11 more
doaj +1 more source
Cytotoxicity of chlorambucil immobilized on magnetic iron oxide nanoparticles Fe3O4
Micro & Nano Letters, 2021 Chlorambucil is a nitrogen mustard alkylating agent used for the treatment of various malignant and non‐malignant cancers. The use of the chemotherapeutic is limited by its toxic side effects which precludes the use of optimal doses.
Julia Nowak‐Jary +2 more
doaj +1 more source
Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapyinduced leukemia [PDF]
, 2001 Glutathione S-transferases (GSTs) detoxify potentially mutagenic and toxic DNA-reactive electrophiles, including metabolites of several chemotherapeutic agents, some of which are suspected human carcinogens.
Allan, J.M. +9 more
core +7 more sources
Frontiers in Veterinary Science, 2022 A 7-year-old castrated male Poodle dog presented with chronic progressive lymphocytosis. Hematologic and peripheral blood smear findings included remarkable lymphocytosis with well-differentiated small lymphocytes. Cytology of bone marrow aspirate showed
Ga-Won Lee +6 more
doaj +1 more source
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]
, 2019 RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat +19 more
core +3 more sources
Antibody as carrier of chlorambucil [PDF]
Cancer, 1972 A surface-localizing heterologous antibody against the mouse Ehrlich ascites carcinoma could be bound to chlorambucil without causing the loss of alkylating activity of chlorambucil or interfering with the reactivity of the antibody with tumor cells. Chlorambucil, when bound to the antibody, was a much more effective tumor inhibitor, both in vitro and ...
M. R. C. Path, S. P. Nigam, T. Ghose
openaire +3 more sources
Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
Frontiers in Pharmacology, 2023 Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated ...
Hongyu Qin +5 more
doaj +1 more source
Unanticipated differences between α- and γ-diaminobutyric acid-linked hairpin polyamide-alkylator conjugates [PDF]
, 2006 Hairpin polyamide–chlorambucil conjugates containing an {alpha}-diaminobutyric acid ({alpha}-DABA) turn moiety are compared to their constitutional isomers containing the well-characterized {gamma}-DABA turn.
Chou, C. James +4 more
core +4 more sources
Chlorambucil-Bearing Hybrid Molecules in the Development of Potential Anticancer Agents
Molecules, 2023 Increasing cases of cancer have been a primary concern in recent decades. Developing new chemotherapeutics is challenging and has been faced with limitations, such as multidrug resistance, poor specificity, selectivity, and toxicity.
Sijongesonke Peter +1 more
doaj +1 more source
Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. [PDF]
, 2004 We studied the actions of geldanamycin (GA) and herbimycin A (HMA), inhibitors of the chaperone proteins Hsp90 and GRP94, on B chronic lymphocytic leukemia (CLL) cells in vitro.
Addison, E +8 more
core +1 more source